Login to Your Account

No Esbriet epaulette, but Prometic revs Ofev study with antifibrotic + mono

By Randy Osborne
Staff Writer

Tuesday, April 18, 2017

Prometic Life Sciences Inc.'s president and CEO, Pierre Laurin, told BioWorld Today that "anything can happen here," as the company pursues work with the oral antifibrotic PBI-4050.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription